imm01
Recombinant proteinexperimental
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Nov 19, 2019 (NCT05860075)
Timeline
Indications
Mechanism of action
- SIRPAANTAGONIST
SIRPA antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07170787 | Phase 1/Phase 2 (Phase 2) | Oct 15, 2025 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
| NCT06600581 | Phase 2 | Dec 15, 2024 | Immunis, Inc. |
| NCT06647862 | Phase 3 | Oct 24, 2024 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd, Tsinghua University, Zhejiang University |
| NCT06465446 | Phase 3 | Jun 30, 2024 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
| NCT05211986 | Phase 1/Phase 2 (Phase 2) | Sep 13, 2022 | Immunis, Inc. |
| NCT05833984 | Phase 1/Phase 2 (Phase 2) | May 17, 2022 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
| NCT05140811 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2022 | Chinese Academy of Medical Sciences, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
| NCT05860075 | Phase 1 | Nov 19, 2019 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
| NCT06784297 | N/A | — | Immunis, Inc. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd | For profit | 6 | 6 | 3 | 2019 |
| Immunis, Inc. | For profit | 3 | 3 | 2 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Tsinghua University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1